Login to Your Account



Durata Files Dalbavancin NDA; Approval Could Occur by May

By Randy Osborne
Staff Writer

Friday, September 27, 2013

The antibiotic dalbavancin’s long road to approval seems likely to end near the end of next May, now that Durata Therapeutics Inc. has submitted the new drug application for the drug targeting acute bacterial skin and skin structure infections.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription